| Project/Area Number |
15K10452
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | Kagoshima University |
|---|
Principal Investigator |
NAGANO Satoshi 鹿児島大学, 医歯学域医学系, 准教授 (50373139)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
小宮 節郎 鹿児島大学, 医歯学域医学系, 教授 (30178371)
瀬戸口 啓夫 鹿児島大学, 医歯学総合研究科, 特任准教授 (40423727)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 骨軟部腫瘍 / 細胞外マトリックス / アンジオテンシン経路 / Tranilast / 細胞周期 / 骨軟部肉腫 / 抗癌剤 / デリバリー / 抗癌剤デリバリー |
|---|
| Outline of Final Research Achievements |
To explore a new treatment for musculoskeletal tumor (MST), we focused on drugs that reduces extracellular matrix (ECM). However, we found no significant role of angiotensin pathway drugs in ECM of MST. Therefore we next focused on anti-allergic drug tranilast, which is known to modulate ECM production by fibroblast. Tranilast inhibited proliferation of osteosarcoma cells in a dose-dependent manner. Combined treatment with tranilast and anti-cancer agents enhanced the cytotoxic effect on osteosarcoma cells. Tranilast enhanced the effect of cisplatin on growth of osteosarcoma xenograft in mice. Because tranilast has been used in clinics without severe side effects for many patients, clinical application in cancer therapy is expected.
|
